- Generic Name:
- Drug Type:
- Bispecific GPRC5D-directed CD3 T-cell engager
- How the Drug is Given:
Injection, for subcutaneous use
Indications and Usage
Talquetamab-tgvs is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Side effects needing medical attention
The most common adverse reactions are fever, Cytokine Release Syndrome, dysgeusia (altered taste in mouth), nail disorder, musculoskeletal pain, skin disorder, rash, fatigue, weight decreased, dry mouth, dry skin, dysphagia (swallowing difficulties), upper respiratory tract infection, diarrhea, hypotension, and headache. The most common laboratory abnormalities are lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, and hemoglobin decreased.